Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada. Show more

1111 Dr. Frederik-Philips Boulevard, Montreal, QC, H4M 2X6, Canada

Biotechnology

Healthcare

Market Cap

162.4M

52 Wk Range

$0.63 - $3.06

Previous Close

$1.31

Open

$1.26

Volume

2,088,242

Day Range

$1.24 - $1.40

Enterprise Value

107.1M

Cash

106M

Avg Qtr Burn

-12.78M

Insider Ownership

2.40%

Institutional Own.

27.09%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CARDAMYST (Etripamil) Details Paroxysmal supraventricular tachycardia	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Etripamil (calcium channel blocker) Details Atrial fibrillation	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cardamyst/Etripamil (Etripamil) (Calcium Channel Blocker) Details Paroxysmal Supraventricular Tachycardia (Pediatric)	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Etripamil (calcium channel blocker) Details Angina, Coronary artery disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.